Compare RDWR & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDWR | XNCR |
|---|---|---|
| Founded | 1996 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2000 | 2013 |
| Metric | RDWR | XNCR |
|---|---|---|
| Price | $29.47 | $19.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $32.50 | $22.33 |
| AVG Volume (30 Days) | 213.0K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $8.62 | $4.80 |
| P/E Ratio | $59.76 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $21.68 | $6.92 |
| 52 Week High | $32.79 | $21.26 |
| Indicator | RDWR | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 70.95 |
| Support Level | $23.45 | $11.28 |
| Resistance Level | $32.36 | N/A |
| Average True Range (ATR) | 1.21 | 1.40 |
| MACD | -0.22 | 0.33 |
| Stochastic Oscillator | 28.96 | 72.67 |
Radware Ltd is a provider of application security and delivery solutions for multi-cloud environments. Its solutions secure the digital experience by providing infrastructure, application, and network protection and availability services to companies globally. Its solutions are deployed by, among others, enterprises, carriers, and cloud service providers. The company offers solutions in two main categories: Products offers a range of cloud-based security-as-a-service subscriptions, on-premises hardware and software products, and product subscriptions (or a combination of these) to customers; and Services offers managed services, professional services, technical support and training and certification to customers and partners.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.